drugset / Trial / NCT03480776

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

NCT03480776

Phase 2 Active not recruiting 117 enrolled Canadian Cancer Trials Group Apotex Inc. · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.

Timeline

Start
2018-07-24
Primary completion
2026-06-30
Completion
2026-09-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aspirin Small molecule 81 mg Oral
Comparator Aspirin Small molecule 325 mg Oral

Indications